Search Results
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
sites.CD20-negative diseaseThere are limited data available on patients with CD20-negative DLBCL and patients with CD20-negative FL treated with Tepkinly, and it is possible that patients with CD20-negative DLBCL and CD20-negative FL may have less benefit compared to patients with CD20-positive
More news about: AbbVie
Jul 06, 2026, 11:19 ET A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
its pipeline beyond its current oncology focus over time.The update arrives as GT Biopharma's clinical programs advance: GTB-3650 (Phase 1, CD33-expressing blood cancers) and GTB-5550 (Phase 1, B7-H3-expressing solid tumors), with the first GTB-5550 patient dosed in May 2026, all built on the
More news about: American News Group
Jul 05, 2026, 23:14 ET Hikvision Jadi Produsen Pertama yang Meraih Sertifikasi EUCC untuk Network Camera
6 Juli, 2026 /PRNewswire/ -- Hikvision mengumumkan keberhasilan produk network camera seri DeepinView (iDS-2CD7x) meraih sertifikat EUCC (European Cybersecurity Certification Scheme on Common Criteria). DeepinView merupakan kamera CCTV pertama di dunia yang memperoleh
More news about: Hikvision
Jul 05, 2026, 13:43 ET Hikvision erhält branchenweit erste EUCC-Zertifizierung für Netzwerkkameras
HANGZHOU, China, 5. Juli 2026 /PRNewswire/ -- Hikvision gab bekannt, dass die DeepinView-Netzwerkkameraserie (iDS-2CD7x) des Unternehmens erfolgreich die EUCC-Zertifizierung (The European Cybersecurity Scheme on Common Criteria) erhalten hat. Dieser Meilenstein steht
More news about: Hikvision
Jul 04, 2026, 12:20 ET Hikvision získava prvú certifikáciu EUCC v odvetví pre sieťové kamery
Čína, 4. júl 2026 /PRNewswire/ -- Spoločnosť Hikvision informovala, že jej séria sieťových kamier DeepinView (iDS-2CD7x) úspešne získala certifikáciu EUCC (Európska schéma certifikácie kybernetickej bezpečnosti na základe spoločných kritérií). Tento míľnik predstavuje
More news about: Hikvision
Jul 04, 2026, 12:13 ET Hikvision conquista a primeira certificação EUCC do setor para câmeras de rede
China, 4 de julho de 2026 /PRNewswire/ -- A Hikvision anunciou que sua série de câmeras de rede DeepinView (iDS-2CD7x) conquistou a certificação EUCC (European Cybersecurity Certification Scheme based on Common Criteria – Estrutura Europeia de Certificação em Cibersegurança
More news about: Hikvision
Jul 03, 2026, 23:12 ET Hikvision、ネットワークカメラにおいて業界初のEUCC認証を取得
中国・杭州、2026年7月4日 /PRNewswire/ -- Hikvisionは、同社のDeepinViewネットワークカメラシリーズ（iDS-2CD7x）が、EUCC（欧州のコモン・クライテリアに基づくサイバーセキュリティスキーム）認証を取得したと発表しました。この画期的な成果は、CCTVカメラ分野において、この権威ある認証を取得した世界初の製品であることを示しており、ロバストな製品セキュリティとコンプライアンスに準拠したデジタルガバナンスに対するHikvisionの取り組みを浮き彫りにしています。
More news about: Hikvision
Jul 03, 2026, 13:47 ET Společnost Hikvision získala jako první v oboru certifikaci EUCC pro síťové kamery
Čína, 3. července 2026 /PRNewswire/ -- Společnost Hikvision oznámila, že její řada síťových kamer DeepinView (iDS-2CD7x) úspěšně získala certifikaci EUCC (Evropského programu kybernetické bezpečnosti podle společných kritérií). Tento milník představuje první produkt
More news about: Hikvision
Jul 03, 2026, 10:01 ET 海康威視網絡攝像機斬獲業內首張EUCC認證
杭州2026年7月3日 /美通社/ -- 海康威視宣布，其DeepinView網絡攝像機系列(iDS-2CD7x)成功獲得EUCC（歐洲通用准則網絡安全認證計劃）認證。這一裡程碑成就，使該產品成為全球閉路電視攝像機品類中首款獲此權威認證的設備，彰顯出海康威視對打造高安全產品、合規開展數字化管理的不懈追求。
More news about: Hikvision
Jul 03, 2026, 05:21 ET Hikvision Earns Industry-First EUCC Certification for Network Cameras
HANGZHOU, China, July 3, 2026 /PRNewswire/ -- Hikvision announced that its DeepinView network camera series (iDS-2CD7x) has successfully obtained the EUCC (The European Cybersecurity Scheme on Common Criteria) certification. This milestone marks the world's first product
More news about: Hikvision
Jul 03, 2026, 04:40 ET Hikvision Earns Industry-First EUCC Certification for Network Cameras
HANGZHOU, China, July 3, 2026 /PRNewswire/ -- Hikvision announced that its DeepinView network camera series (iDS-2CD7x) has successfully obtained the EUCC (The European Cybersecurity Scheme on Common Criteria) certification. This milestone marks the world's first product
More news about: Hikvision
Jul 02, 2026, 19:29 ET Cognizant 與 OpenAI 推進前沿 AI 網絡安全防禦：從發現漏洞到經驗證的修復方案
擁有網絡安全領域的深厚知識和交付規模，能協助企業負責任地應用這些能力，並具備從發現到經驗證修復所需的監督及管治機制。」Cognizant 在將這些能力提供給客戶之前，以自身作為「零號客戶」(Client Zero)，率先在自身安全營運中加以應用。 公司安全團隊在內部防禦工作流程中，運用配備「網絡安全受信任存取計劃」的 GPT-5.5，涵蓋安全程式碼審查、漏洞分級與驗證，以及 Pull Request（拉取請求）和持續 CI/CD 安全審查，每個步驟均有人工驗證和監督。 於自身環境中，Cognizant 正將這些能力應用於其各項產品、平台及內部程式碼庫，以加速漏洞管理的生命週期，由發現、驗證以至修復全面覆蓋。 這份從自身資產中累積而來的營運經驗，正是 Cognizant 帶給客戶合作項目的價值。Cognizant
More news about: Cognizant Technology Solutions
Jul 02, 2026, 19:14 ET Cognizant e OpenAI trazem a vanguarda da ciberdefesa com IA, desde a descoberta de vulnerabilidades até correções validadas
trabalho internos de defesa, incluindo revisão segura de código, triagem e validação de vulnerabilidades, além de revisão de segurança de pull request e CI/CD, com validação e supervisão humana em cada etapa. Em seu próprio ambiente, a Cognizant aplica essas capacidades em todo o seu portfólio de produtos,
More news about: Cognizant Technology Solutions
Jul 02, 2026, 19:11 ET Cognizant y OpenAI llevan la ciberdefensa con IA de vanguardia del descubrimiento de vulnerabilidades a las correcciones validadas
revisión segura de código, la clasificación y validación de vulnerabilidades, la revisión de seguridad de integración continua (CI) y despliegue continuo (CD) y solicitudes de incorporación de cambios, con validación y supervisión humana en cada paso. En su propio entorno, Cognizant está aplicando estas
More news about: Cognizant Technology Solutions
Jul 02, 2026, 14:13 ET Cognizant und OpenAI bringen modernste KI-Cyberabwehr von der Schwachstellenerkennung bis hin zu validierten Korrekturen
Cyber" in internen Abwehrprozessen ein, darunter sichere Codeprüfung, Triage und Validierung von Schwachstellen sowie Pull-Request- und CI/CD-Sicherheitsprüfungen, wobei jeder Schritt durch menschliche Überprüfung und Aufsicht begleitet wird. In seiner eigenen Umgebung setzt Cognizant diese Fähigkeiten
More news about: Cognizant Technology Solutions
Jul 02, 2026, 12:52 ET Cognizant en OpenAI brengen frontier AI-cyberverdediging van kwetsbaarheidsontdekking tot gevalideerde oplossingen
Trusted Access for Cyber voor interne defensieve workflows, waaronder beveiligde code review, vulnerability triage en validatie en pull-request en CI/CD beveiliging review, met menselijke validatie en toezicht bij elke stap.In zijn eigen omgeving past Cognizant deze mogelijkheden toe op zijn reeks
More news about: Cognizant Technology Solutions
Jul 02, 2026, 10:46 ET Global DNA Diagnostics Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight
Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation, NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics, HTG Polymerase Chain Reaction, Inc., and others.
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 09:00 ET Cognizant and OpenAI bring frontier AI cyber defense from vulnerability discovery to validated fixes
Trusted Access for Cyber across internal defensive workflows, including secure code review, vulnerability triage and validation and pull-request and CI/CD security review, with human validation and oversight at every step. In its own environment, Cognizant is applying these capabilities across its
More news about: Cognizant Technology Solutions
Jul 02, 2026, 09:00 ET Cognizant et OpenAI mettent en œuvre une IA d'avant-garde pour la cyberdéfense, de l'identification des vulnérabilités à la validation des correctifs
vulnérabilités, ainsi que l'examen de la sécurité des demandes de type « pull-request » et des pipelines d'intégration et de déploiement continus (CI/CD), avec une validation et une supervision humaines à chaque étape. Dans son propre environnement, Cognizant met en œuvre ces capacités sur l'ensemble
More news about: Cognizant Technology Solutions
Jul 01, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Jul 01, 2026, 14:12 ET Researchers from World's No. 1 Reproductive Immunology Program Address Infertility at ASRI Annual Meeting
Impaired Immune Plasticity in Reproductive Failure: Differential Effects of BMP-7 and SOD3 on CXCR3/CXCR4/CD54 Expression" was presented by Dr. Han, Dr. Ganieva, Dr. Dambaeva, and Dr. Kwak-Kim."
More news about: Rosalind Franklin University of Medicine and Science
Jul 01, 2026, 10:46 ET Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight
understanding of market trends, market drivers, market barriers, and key cancer diagnostics companies, including Pillar Biosciences, Inc., Hologic Inc., CD Genomics, Natera, Inc., Agendia Inc., Biodesix Inc., INOVIQ Ltd., HTG Molecular Diagnostics Inc., Bio-Rad Laboratories, Inc., Koninklijke Philips N.V.,
More news about: DelveInsight Business Research, LLP
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
Pharmaceuticals with Olutasidenib + TMZ, Aminex Therapeutics with AMXT1501, Bexion Pharmaceuticals with BXQ-350, OX2 Therapeutics with CD200ARL, and Neonc Technologies with NEO100, among others.High-grade Glioma Competitive LandscapeSome of the high-grade glioma
More news about: DelveInsight Business Research, LLP
Jun 30, 2026, 12:05 ET Free People to Open New Store in Palm Desert, CA on July 3, 2026
https://app.viralsweep.com/sweeps/full/27cd62-229759?framed=1
More news about: Free People
Jun 30, 2026, 09:00 ET A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
with potential targets and indications expanding beyond oncology.The update arrives as its clinical programs advance: GTB-3650 (Phase 1, CD33-expressing blood cancers) and GTB-5550 (Phase 1, B7-H3-expressing solid tumors), with the first GTB-5550 patient dosed in May 2026.Other
More news about: USA News Group